Most people make bad decisions. The lucky thing is most of them don't have to look at the reminders of those decisions on ...

The author elegantly explores the interplay of past and the present as a mother and son reunite in Tokyo after a decade of estrangement ...

1. Someone really took some time and effort to do this, and I just want them to know that I appreciate it. 11. This guy's girlfriend got him a Christmas card that makes, uh, sensual noises when you ...

Nearly two-thirds of marketers believe advancements in artificial intelligence will reshape their role dramatically within the next two years, but many still struggle to tie the technology to results, ...

This is read by an automated voice. Please report any issues or inconsistencies here. Viral videos show ICE agents bungling arrests as detainees slip away, run from agents or evade capture in scenes ...

Last season’s return to European football after a year away from it was supposed to be useful preparation for this totally rebuilt Chelsea squad. In fact, it looks like it’s had the opposite effect.

Please provide your email address to receive an email when new articles are posted on . Low-dose methotrexate did not relieve pain or reduce synovitis in inflammatory knee OA. The findings do not ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...

Vertex Pharmaceuticals said Monday afternoon that its next-generation non-opioid pain reliever failed to significantly out-perform placebo in a Phase 2 trial. The experimental drug, codenamed VX-993, ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...